Evidence map›Paper›PMID 34558862›Full record

ArticleHepatology communications2022

Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.

Ashwini Arvind, Jacqueline B Henson, Stephanie A Osganian, Cheryl Nath, Lara M Steinhagen, Zoe N Memel, Arley Donovan, Oluwafemi Balogun, Raymond T Chung, Tracey G Simon and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Dysfunctional VLDL metabolism in MASLD.npj metabolic health and disease · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ashwini ArvindHarvard Medical School, Boston, MA, USA.
Jacqueline B HensonHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-3488-6615
Stephanie A OsganianLiver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA.
Cheryl NathLiver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA.
Lara M SteinhagenLiver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA.
Zoe N MemelHarvard Medical School, Boston, MA, USA.
Arley DonovanLiver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA.
Oluwafemi BalogunLiver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA.
Raymond T ChungHarvard Medical School, Boston, MA, USA.
Tracey G SimonHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-0610-5287
Kathleen E CoreyHarvard Medical School, Boston, MA, USA.
Harvard University · USMassachusetts General Hospital · US

Funding

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskR01DK114144 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI COREY, KATHLEEN ELIZABETH, STANLEY, TAKARA LEAH · 2018 to 2022
$4.0M
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver DiseaseK23DK122104 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI SIMON, TRACEY · 2019 to 2023
$1.1M
NIDDK NIH HHS K23 DK122104NIDDK NIH HHS R01 DK114144
6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD. NAFLD is increasingly seen in individuals who are lean and overweight (i.e., nonobese), but it is unclear whether their risk of CVD is comparable to those with NAFLD and obesity. Using a prospective cohort of patients with NAFLD, we compared the prevalence and incidence of CVD in individuals with and without obesity. NAFLD was diagnosed by biopsy or imaging after excluding other chronic liver disease etiologies. Logistic regression was used to compare the odds of baseline CVD by obesity status. Cox proportional hazards regression was used to evaluate obesity as a predictor of incident CVD and to identify predictors of CVD in subjects with and without obesity. At baseline, adults with obesity had a higher prevalence of CVD compared to those without obesity (12.0% vs. 5.0%, P = 0.02). During follow-up, however, obesity did not predict incident CVD (hazard ratio [HR], 1.24; 95% confidence interval [CI], 0.69-2.22) or other metabolic diseases. Findings were consistent when considering body mass index as a continuous variable and after excluding subjects who were overweight. Age (adjusted HR [aHR], 1.05; 95% CI, 1.03-1.08), smoking (aHR, 4.61; 95% CI, 1.89-11.22), and decreased low-density lipoprotein levels (aHR, 0.98; 95% CI, 0.96-1.00) independently predicted incident CVD in the entire cohort, in subjects with obesity, and in those without obesity, respectively. Conclusion: Individuals with overweight or lean NAFLD are not protected from incident CVD compared to those with NAFLD and obesity, although CVD predictors appear to vary between these groups. Patients without obesity also should undergo rigorous risk stratification and treatment.

Indexed as

AdultBody Mass IndexCardiovascular DiseasesFemaleHeart Disease Risk FactorsHumansIncidenceMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseObesityOverweightPrevalenceProportional Hazards ModelsProspective StudiesThinness

Identifiers

PMID34558862
PMCPMC8793991
OpenAlexW3196995864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.